1992 年建立的 NK-92 细胞系具有高度活性的天然杀伤细胞 (NK) 细胞的所有特征，但具有更广泛和更强的细胞毒性。该细胞系由淋巴瘤患者的血细胞建立，并自 1998 年起被广泛用于研究，存放在美国类型细胞收藏中心。 全球范围内 NK-92 细胞的分发导致大量的科学发现，大大增加了对 NK-细胞生物学的理解。 NK-92 细胞还被开发用于临床使用，克服了从捐赠者或患者血液中获得和扩大 NK 细胞的挑战。 现已有超过100位癌症患者全球范围内接受未修改或基因工程改造的 NK-92 细胞治疗。 修改的细胞包括高亲和力的 Fc 受体表达的 NK-92 细胞 (haNKR) 和各种嵌合抗原受体靶向的 haNK 细胞 (t-haNKTM)。 报告 NK-92 细胞的输注是安全和有效的，有时即使在先前多次失效的患者中，也可以导致疾病缓解。 本文的目的是提炼对 NK-92 细胞及其基因变异的大量科学数据，突出相关实验发现，有助于更好地理解 NK 细胞生物学，并概述这些细胞在治疗癌症和感染方面的治疗潜力。 版权所有 © 2022 国际细胞与基因治疗学会。 由 Elsevier Inc. 发布。 保留所有权利。

The NK-92 cell line, established in 1992, mirrors all the characteristics of highly active blood natural killer (NK) cells but with much broader and greater cytotoxicity. The cell line was established from the blood cells of a patient with lymphoma and has been made widely available for research since it was deposited into the American Type Culture Collection in 1998. The worldwide distribution of NK-92 cells has led to a plethora of scientific discoveries that have greatly increased the understanding of NK-cell biology. NK-92 cells also have been developed for clinical use, overcoming the challenges of obtaining and expanding NK cells from donor or patient blood. More than 100 patients with cancer have now been treated all over the world with unmodified or genetically engineered NK-92 cells. Modified cells include high-affinity Fc-receptor expressing NK-92 cells (haNKR) and various chimeric antigen receptor targeted haNK cells (t-haNKTM). Infusions of either unmodified or modified NK-92 cells have been reported to be safe and efficacious, leading in some cases to disease remission even in patients who had failed multiple previous lines of therapy. It is the purpose of this review to distill the plethora of scientific data on NK-92 cells and its genetic variants, highlighting relevant experimental findings that have contributed to a better understanding of NK cell biology and summarize the therapeutic potential of these cells for treatment of cancer and infections.Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.